Dynavax Technologies Corporation (NASDAQ:DVAX) [Trend Analysis] moved down reacts as active mover, shares a loss -1.07% to traded at $13.85 and the percentage gap among open changing to regular change was -0.14%. Dynavax (DVAX) offers regulatory update on HEPLISAV-B; FDA will review the overall immunogenicity data from HBV-23.
Dynavax Technologies (DVAX) revealed that the FDA Center for Biologics Evaluation and Research has cancelled the planned November 16, 2016, Vaccines and Related Biological Products Advisory Committee meeting to review the Biologics License Application for HEPLISAV-B. During recent conversations among Dynavax and the FDA, the Agency communicated decisions to enable compliance with the current PDUFA date of December 15, 2016. The Agency informed Dynavax that the VRBPAC meeting was cancelled and remaining questions will be addressed among Dynavax and the review team via the normal process. The firm’s current ratio calculated as 5.20 for the most recent quarter. The firm past twelve months price to sales ratio was 143.16 and price to cash ratio remained 5.66. As far as the returns are concern, the return on equity was recorded as -64.40% and return on investment was -57.10% while its return on asset stayed at -55.60%. The firm has total debt to equity ratio measured as 0.
GlaxoSmithKline plc (NYSE:GSK) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -0.25% to $43.88. GlaxoSmithKline (GSK) and Innoviva (INVA) revealed that the results from the pioneering Salford Lung Study have been published in the New England Journal of Medicine. This study, which reported headline results in May 2016, was deinked to evaluate the effectiveness and safety of Relvar Ellipta in patients with chronic obstructive pulmonary disease as compared with their ‘usual care’ administered in an everyday clinical practice setting. Data from the study are being presented at the European Respiratory Society International Congress on Sunday 4th September in London. The share price of GSK attracts active investors, as stock price of week volatility recorded 0.84%. The stock is going forward to its 52-week low with 26.35% and lagging behind from its 52-week high price with -2.64%.
Intuit Inc. (NASDAQ:INTU) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.05% to close at $111.31 with the total traded volume of 53213 shares. The firm has institutional ownership of 88.50%, while insider ownership included 0.10%. Its price to sales ratio ended at 6.09. INTU attains analyst recommendation of 2.60 with week performance of 0.55%.